



- (51) International Patent Classification:
A61B 17/00 (2006.01)
- (21) International Application Number:
PCT/US2013/040069
- (22) International Filing Date:
8 May 2013 (08.05.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/645,372 10 May 2012 (10.05.2012) US
- (71) Applicant: **EMPIRE TECHNOLOGY DEVELOPMENT LLC** [US/US]; 2700 Centerville Road, Suite 400, Wilmington, DE 19808 (US).
- (72) Inventors: **ADAMS, John**; 18023 Fales Road, Snohomish, WA 98296 (US). **HAWKINS, Daniel**; 5563 156th Ave Se, Bellevue, WA 98006 (US).
- (74) Agent: **CHRISTENSEN, Michael, R.**; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DEVICE AND METHOD FOR TREATING DIVERTICULAR DISEASE




FIG. 11

(57) Abstract: Disclosed herein are methods and devices for treating diverticular disease. The method can include injecting a sterile fluid between a mucosal layer of the diverticulum and a serosal layer of the diverticulum to form an expanded cavity in the diverticulum comprising the sterile fluid; injecting a filler material in the expanded cavity; and removing at least a portion of the sterile fluid from the expanded cavity. The device can include a flexible overtube having a lumen; a flexible shaft at least partially disposed within the lumen of the flexible overtube; a cutting tip at a distal end of the flexible shaft; an input port fluidly coupled to the lumen of the flexible shaft; and an output port fluidly coupled to a proximal end of the lumen of the overtube. Also disclosed herein are systems and kits for treating diverticular disease.



DEVICE AND METHOD FOR TREATING DIVERTICULAR DISEASE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit of U.S. Provisional Patent App. No. 61/645,372, filed on May 10, 2012, the contents of which are incorporated herein by reference in their entirety.

BACKGROUND

[0002] An outpouching of the colon or other body lumen, called a diverticulum, can become the site for inflammation known as diverticulitis, microperforation and/or bleeding. Current treatments may involve the surgical removal of segments of the body lumen. For extreme cases of diverticulitis, treatment can involve colon resection and placement of a colostomy. This approach results in significant healthcare costs and substantial pain for patients.

SUMMARY

[0003] The foregoing summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features will become apparent by reference to the drawings and the following detailed description.

[0004] A method for treating a diverticulum formed in a body lumen. The method can include: injecting a sterile fluid between a mucosal layer of the diverticulum and a serosal layer of the diverticulum to form an expanded cavity in the diverticulum containing the sterile fluid; injecting a filler material in the expanded cavity; and removing at least a portion of the sterile fluid from the expanded cavity.

[0005] A needle for treating a diverticulum formed in a body lumen. The needle can include: a flexible overtube having a lumen; a flexible shaft at least partially disposed within the lumen of the flexible overtube; a cutting tip at a distal end of the flexible shaft, the cutting tip having an opening fluidly coupled to the lumen of the flexible shaft; an input port fluidly coupled to the opening of the cutting tip; and an output port fluidly coupled to a proximal end of the lumen of the overtube. The flexible shaft can be configured to adjustably extend from a distal end of the flexible overtube.

[0006] A kit for treating a diverticulum formed in a body lumen. The kit can include: a flexible tubular assembly, a light source, a lens, and a needle. The flexible tubular assembly can be configured to be advanced in a body lumen. The light source can be configured to be at least partially disposed within a first lumen of the flexible tubular assembly. The lens can be configured to be at least partially disposed within a second lumen of the flexible tubular assembly. The needle can be configured to be at least partially disposed within a third lumen of the flexible tubular assembly. The needle can include: a flexible overtube having a lumen; a flexible shaft at least partially disposed within the lumen of the flexible overtube; a cutting tip at a distal end of the flexible shaft; an input port; and an output port. The flexible shaft can be configured to adjustably extend from a distal end of the flexible overtube. The cutting tip can include an opening fluidly coupled to the lumen of the flexible shaft. The input port can be fluidly coupled to the opening of the cutting tip. The output port can be fluidly coupled to a distal end of the lumen of the overtube.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The foregoing and other features of the present disclosure will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only several embodiments in accordance with the disclosure and are not to be considered limiting of its scope, the disclosure will be described with additional specificity and detail through use of the accompanying drawings.

[0008] **FIGURE 1** is a sectional view of a diverticulum of the sigmoid colon.

[0009] **FIGURE 2** is a flow diagram showing one example of a method for treating a diverticular disease within the scope of the present application.

[0010] **FIGURE 3** is a view of a working end of a colonoscope that can be advanced through the intestine of a subject.

[0011] **FIGURE 4** is a side view of a colonoscope bent to view a diverticulum of the sigmoid colon.

[0012] **FIGURE 5** is a perspective and partial sectional view of a needle configured to be disposed within the lumen of the tubular assembly.

[0013] **FIGURE 6** is a side view of a needle inserted into a region of the diverticulum between the mucosal layer and the serosal layer.

[0014] **FIGURE 7** is a side view of an expanded cavity initially formed in the diverticulum by injecting a sterile fluid.

[0015] **FIGURE 8** is a side view of an expanded cavity that fills the diverticulum.

[0016] **FIGURE 9** is a side view of a needle having a distal end of an overtube inserted into the expanded cavity.

[0017] **FIGURE 10** is a side view of the expanded cavity after initially inserting a filler material.

[0018] **FIGURE 11** is a side view of the expanded cavity after additional filler material is inserted.

[0019] **FIGURE 12** is a side view of the expanded cavity filled with filler material.

[0020] **FIGURE 13** shows the proximal end of a needle while removing sterile fluid from an expanded cavity.

DETAILED DESCRIPTION

[0021] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be used, and other changes may be made, without departing from the spirit or scope of the subject matter presented here. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, and designed in a wide variety of different configurations, all of which are explicitly contemplated and make part of this disclosure.

[0022] Disclosed herein are methods and devices for treating diverticular disease. The method can include injecting a sterile fluid between a mucosal layer of the diverticulum and a serosal layer of the diverticulum to form an expanded cavity in the diverticulum comprising the sterile fluid; injecting a filler material in the expanded cavity; and removing at least a portion of the sterile fluid from the expanded cavity. The device can include a flexible overtube having a lumen; a flexible shaft at least partially disposed within the lumen of the flexible overtube; a cutting tip at a distal end of the flexible shaft; an input port fluidly coupled to the lumen of the flexible shaft; and an output port fluidly coupled to a proximal end of the

lumen of the overtube. Also disclosed herein are systems and kits for treating diverticular disease.

[0023] **FIGURE 1** is a sectional view of a diverticulum of the sigmoid colon. Sigmoid colon **100** includes mucosal layer **120**, muscular layer **130**, and serosal layer **140**. Diverticulum **110** is one example of a diverticulum that can be treated using the devices and methods disclosed in the present application. Diverticulum **110** is located at gap in muscular layer **130** and includes mucosal **120** and serosal layer **140**. The depth of a diverticulum is typically about 1-2 cm.

[0024] **FIGURE 2** is a flow diagram showing one example of a method for treating a diverticular disease within the scope of the present application. The method of treating diverticular disease can include: “Advancing a flexible tubular assembly through a body lumen,” illustrated in block **200**; “Disposing a flexible needle within a lumen of the tubular assembly,” illustrated in block **210**; “Inserting a distal end of the flexible needle into a region of the diverticulum between the mucosal layer and the serosal layer,” illustrated in block **220**; “Injecting a sterile fluid into the region of the diverticulum between the mucosal layer and the serosal layer to form an expanded cavity,” illustrated in block **230**; “Inserting an overtube into the expanded cavity,” illustrated in block **240**; “Injecting a filler material into the expanded cavity,” illustrated at block **250**; and “Removing at least a portion of the sterile fluid from the expanded cavity,” illustrated in block **260**. Although operations **210** – **260** may be performed sequentially, it will be appreciated that one or more of these operations may be performed at about the same time. These operations may also be performed in a different order than is depicted in **FIGURE 2**.

[0025] At operation **200** “Advancing a flexible tubular assembly through a body lumen,” a flexible tubular assembly can be moved through a body lumen to a location near a diverticulum in the body lumen. **FIGURE 3** is a view of a working end of a colonoscope that can be advanced through the intestine of a subject. Colonoscope **300** is one example of a tubular assembly that can be used in the methods and devices for treating diverticular disease of the present application. Colonoscope **300** includes light source **310** configured to illuminate an area for viewing; viewing lens **320** configured to provide a user, such as a surgeon, with a field of vision; lumen **330** which can include a water source for flushing, a source of air, and/or a source of negative pressure; and working channel **340** through which tools such as biopsy forceps, graspers, or manipulators are typically passed. Colonoscopes are

typically flexible and can be manipulated to bend and articulate along segments up to about 180 degrees. The dimensions of the colonoscope can vary, but may have a diameter from about 6 mm to about 20 mm and a length about 1 m to about 2 m. Working channel **340** can, for example, have a diameter of about 2 mm to about 5 mm.

[0026] The tubular assembly can be inserted into a body cavity or passageway, such as a colon, intestine, esophagus, etc. to treat the diverticular disease. As an example, the tubular assembly can be passed through the anus of a subject to reach the intestine. The intestine can be visually inspected (e.g., using light source **310** and viewing lens **320** on colonoscope **300**) to identify one or more diverticula. **FIGURE 4** is a side view of a colonoscope bent to view a diverticulum of the sigmoid colon. Colonoscope **300** has suitable flexibility to bend about 90 degrees for viewing diverticulum **110**.

[0027] Returning to **FIGURE 2**, at operation **210** “Disposing a flexible needle within a lumen of the tubular assembly,” a needle can be inserted into a lumen of the tubular assembly for accessing the diverticulum. As an example, after identifying a diverticulum in the colon using colonoscope **300**, a needle can be at least partially disposed in working channel **340** of colonoscope **300** to access diverticulum **110**. Alternatively, the needle may be disposed in working channel **340** of colonoscope **300** before advancing colonoscope **300** through sigmoid colon **100**.

[0028] **FIGURE 5** is a perspective and partial sectional view of a needle configured to be disposed within the lumen of the tubular assembly. Needle **500** includes sclerotherapy needle **510** having cutting tip **520** and opening **530** at a distal end. Sclerotherapy needle **510** is disposed within a lumen of overtube **540** and can be configured to adjustably extend from opening **550** at distal end of overtube **540** (e.g., sclerotherapy needle **510** can extend up to about 2 cm from opening **550**). Needle **500** also includes input port **560** and output port **570**. Input port **560** is fluidly coupled to opening **530** of sclerotherapy needle **510** and configured so that a fluid can be injected from input port **560**. As an example, input port **560** can include a luer lock that couples to a syringe containing a fluid for injection. Output port **570** is fluidly coupled to opening **550** of overtube **540** so that a fluid can be withdrawn from opening **550** towards output port **570**. For example, output port **570** can include a luer lock that couples to an empty syringe that can withdraw fluid by pulling the plunger on the syringe. The dimensions of the needle may vary so long as they can be disposed within the tubular assembly. As an example, needle **500** may be longer than

colonoscope **300** and have a diameter less than the diameter of working channel **340** of colonoscope **300** (e.g., overtube **540** has a diameter of no more than about 3 mm). Needle **500** can have suitable flexibility for advancing through working channel **340** of colonoscope **300** while positioned in a body lumen.

[0029] Sclerotherapy needle **510** also includes marking **580** at fixed distance **590** from a distal end of sclerotherapy needle **510** (e.g., near cutting tip **520** and/or opening **530**). Fixed distance **590** can be about the same as the depth of a region between the mucosal layer and the serosal layer of the diverticulum. For example, fixed distance **590** can be about 1 mm to about 3 mm. As discussed further below, a user may utilize marking **580** to determine when opening **530** has been disposed within the region between the mucosal layer and the serosal layer.

[0030] Returning to **FIGURE 2**, at operation **220** “Inserting a distal end of the flexible needle into a region of the diverticulum between the mucosal layer and the serosal layer,” the needle is inserted into the diverticulum so that a fluid can be injection between mucosal layer and serosal layer. As an example, cutting tip **520** of needle **500** can pierce through mucosal layer **120** at or near diverticulum **110** so that opening **530** of needle **500** is disposed between mucosal layer **120** and serosal layer **140**. The needle can be guided into the appropriate region using standard endoscopic techniques. An appropriate depth for inserting needle **500** can optionally be determined by viewing the location of marking **580**. For example, when marking **580** is at or near mucosal layer **120**, this may indicate that opening **530** of needle **500** is at an appropriate location between the mucosal layer and the serosal layer.

[0031] **FIGURE 6** is a side view of a needle inserted into a region of the diverticulum between the mucosal layer and the serosal layer. Needle **500** extends from working channel **340** of colonoscope **300** through mucosal layer **120** of sigmoid colon **100**. The distal end of overtube **540** and the distal end of sclerotherapy needle **510** can be on opposite sides of mucosal layer **120**.

[0032] Returning again to **FIGURE 2**, at operation **230** “Injecting a sterile fluid into the region of the diverticulum between the mucosal layer and the serosal layer to form an expanded cavity,” a sterile fluid can be injected using the needle to form an expanded cavity. As an example, a syringe containing a sterile fluid can be coupled to input port **560** of needle **500** and the plunger of the needle can be depressed to displace the sterile fluid into the region

of the diverticulum between the mucosal layer and the serosal layer. The sterile fluid can be saline or other isotonic, biocompatible liquids.

[0033] **FIGURE 7** is a side view of an expanded cavity initially formed in the diverticulum by injecting a sterile fluid. While initially injecting sterile fluid **700**, an expanded cavity forms between mucosal layer **120** and serosal layer **140** near the distal end of sclerotherapy needle **510**. The pressure of sterile fluid **700** can spread apart mucosal layer **120** from serosal layer **140** at diverticulum **110** to form the expanded cavity.

[0034] During injection, a user may observe the site of injection to confirm that an expanded cavity is forming and, if needed, adjust the needle location or rate of injection accordingly. Furthermore, the pressure can optionally be monitored to reduce the likelihood of rupturing or tearing of the expanded cavity. As an example, if the fluid pressure increases above a pre-determined threshold, the rate of injection can be reduced. The pressure can be monitored using a suitable pressure sensor fluidly coupled to the needle. The fluid delivery and pressure can also be automated. For example, the fluid may be injected using a pump and monitored using a pressure sensor. Both the pump and pressure sensor can be coupled to a processor that is configured to adjust the rate of injection based, at least in part, on the measured pressure.

[0035] The volume of sterile fluid can also be monitored and the injection discontinued when a pre-determined volume is obtained. Also, as discussed further below, the total volume of sterile fluid injected may be measured and used to determine an appropriate volume of filler material to inject within the expanded cavity.

[0036] **FIGURE 8** is a side view of an expanded cavity that fills the diverticulum. After continued injection of fluid **700**, mucosal layer **120** and serosal layer **140** may be separated such that mucosal layer **120** is located near the inner wall of sigmoid colon **100**. Injection of the sterile fluid can be discontinued when the mucosal layer reaches near the inner wall or a pre-determined volume of sterile fluid has been injected. The expanded cavity may have a volume that is about the same as the volume of the diverticulum before injecting the sterile fluid.

[0037] Returning to **FIGURE 2**, at operation **240** "Inserting an overtube into the expanded cavity," an overtube can be inserted through the mucosal layer into the expanded cavity. For example, the distal end of the overtube can be advanced about 3-4 mm below the mucosal layer into the expanded cavity. **FIGURE 9** is a side view of a needle having a distal

end of an overtube inserted into the expanded cavity. Overtube **540** has opening **550** disposed within the expanded cavity containing sterile fluid **700**. Overtube **540** can be configured so that sterile fluid **700** can be removed from the expanded cavity via overtube **540** and received at output port **570**. Sclerotherapy needle **510** can be extended from the distal end of overtube **540** in a direction from mucosal layer **120** toward serosal layer **140**. For example, sclerotherapy needle **510** can be advanced about 8-10 mm further into the expanded cavity.

[0038] Returning to **FIGURE 2**, at operation **250** “Injecting a filler material into the expanded cavity,” the expanded cavity is filled with an appropriate filler material using the needle. As an example, a syringe containing the filler material can be coupled to input port **560** of needle **500** and the plunger of the needle depressed to inject the filler material into the expanded cavity. **FIGURE 10** is a side view of the expanded cavity after initially inserting a filler material. Sclerotherapy needle **510** is extended so that filler material **1000** is initially placed near serosal layer **140** of the expanded cavity. Sterile fluid **700** can be disposed between filler material **1000** and mucosal layer **120**.

[0039] **FIGURE 11** is a side view of the expanded cavity after additional filler material is inserted. As filler material **1000** is injected in the expanded cavity, the volume of filler material **1000** increases and the distance between filler material **1000** and mucosal layer **120** can decrease. Opening **530** of sclerotherapy needle **510** can be moved from serosal layer **140** to mucosal layer **120** (e.g., sclerotherapy needle **510** can be retracted into the lumen of overtube **540**) as the volume of filler material **1000** in the expanded cavity increases. Moving opening **530** of sclerotherapy needle **510** towards mucosal layer **120** may reduce or prevent entrapping sterile fluid **700** between filler material **1000** and serosal layer **140**.

[0040] **FIGURE 12** is a side view of the expanded cavity filled with filler material. The volume of expanded cavity can be about the same as the volume of filler material **1000**. Sclerotherapy needle **510** can be disposed near mucosal layer **120** after the expanded cavity is filled with filler material **1000**. The volume of filler material injected into the expanded cavity is not particularly limited. For example, the volume of filler material injected into the expanded cavity can be about the same as the volume of sterile fluid injected into the expanded cavity (e.g., the volume of filler material injected at operation **240** depicted in **FIGURE 2** is about the same as the volume of sterile fluid injected at operation **220** as depicted in **FIGURE 2**). The volume of filler material injected can be determined by monitoring the volume of filler material in a syringe, or using a volumetric sensor fluidly coupled to input port **560** of needle

500. As another example, the volume of filler material injected into the expanded cavity can be determined by pressure measurements. A user may discontinue injecting the filler material when a measured pressure of the filler material obtains a pre-determined threshold. The pressure can be determined using, for example, a pressure sensor coupled to input port **560** of needle **500**.

[0041] The filler material can be configured so that scar tissue forms in the expanded cavity. The filler material may include a polymer, a polysaccharide, hydrophilic colloids, sclerosing agents, microspheres, autologous cells, fibrous, organic, inorganic or a mixture thereof. Suitable fillers include synthetic polymers derived from vinyl, acrylate, methacrylate, urethane, ester and oxide monomers, naturally occurring polysaccharides such as chitin, chitosan, dextran and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum and scleroglucan; starches such as dextrin and maltodextrin; hydrophilic colloids such as pectin; phosphatides such as lecithin; alginates such as ammonia alginate, sodium, potassium or calcium alginate, propylene glycol alginate; gelatin; collagen; and cellulosics such as ethyl cellulose (EC), methylethyl cellulose (MEC), Carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose acetate succinate (HPMCAS), hydroxypropylmethyl cellulose acetate trimellitate (HPMCAT), and ethylhydroxy ethylcellulose (EHEC). Other materials useful as the filler include, but are not limited to, pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl acetate, glycerol fatty acid esters, polyacrylamide, polyacrylic acid, copolymers of ethacrylic acid or methacrylic acid and other acrylic acid derivatives such as homopolymers and copolymers of butylmethacrylate, methylmethacrylate, ethylmethacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and (trimethylaminoethyl)methacrylate chloride.

[0042] Returning to **FIGURE 2**, at operation **260** "Removing at least a portion of the sterile fluid from the expanded cavity," the sterile fluid can be removed from the expanded so that filler material can be disposed in the expanded cavity. The sterile fluid can be removed before, during, or after injecting the filler material (e.g., operation **260** depicted in **FIGURE 2** can be performed before, after, and/or at about the same time as operation **250** depicted in

FIGURE 2). The sterile fluid can be removed through opening **550** of overtube **500** and received at output port **570**. Output port **570** can optionally be coupled to a reservoir that receives the sterile fluid. The reservoir can include markings for determining a volume of sterile fluid received. Output port **550** can also optionally be coupled to a volumetric sensor for measuring a volume or weight of sterile fluid removed from the expanded cavity.

[0043] **FIGURE 13** shows the proximal end of a needle while removing sterile fluid from an expanded cavity. Input port **560** of needle **500** is fluidly coupled to syringe **1300** containing filler material **1000**. The plunger of syringe **1300** can be depressed to inject filler material into the expanded cavity via sclerotherapy needle **510**. As filler material **1000** displaces into the expanded cavity (e.g., as depicted in **FIGURES 9** and **10**), sterile fluid **700** displaces from the expanded cavity into reservoir **1310** via overtube **540**. A negative pressure can optionally be applied to overtube **540** using, for example, a vacuum fluidly coupled to output port **570** to aid withdrawal.

[0044] The volume of sterile fluid removed from the expanded cavity (e.g., sterile fluid **700** in reservoir **1310** depicted in **FIGURE 13**) can be monitored. For example, when the volume of sterile fluid removed from the expanded cavity is about the same as the volume of sterile fluid injected into the expanded cavity (e.g., sterile fluid injected during operation **220** as depicted in **FIGURE 2**), a user can discontinue injecting filler material into the expanded cavity. This procedure may be automated using volumetric sensors and/or pressure sensors that are coupled to input port **560** and/or output **570**, and an appropriate pump (e.g., syringe pump or Harvard pump), each coupled to a processor configured automate injecting the filler material until a pre-determined threshold (e.g., pressure of filler material, volume of sterile fluid removed, or volume of filler material injected) is obtained.

[0045] After the expanded cavity has been filled with an appropriate amount of filler material, the needle can be removed from the expanded cavity. The hole in the mucosal layer formed by the needle can be optionally closed using sutures or an appropriate adhesive. The tubular assembly may then be used to search for additional diverticula. If one or more additional diverticula are present, the tubular assembly can be disposed near a second diverticulum and the treatment can be repeated (e.g., operations **200** – **260** as depicted in **FIGURE 2** are repeated on the second diverticulum). The repeated treatments can be completed without removing the tubular assembly from the intestine, and optionally, without removing the needle from the working channel.

[0046] While the description generally refers to colonoscopes and treatments within a colon, the devices and methods described herein are not limited to applications within a colon. They can be used to invert and/or treat outpocketings (e.g., diverticula, aneurisms, etc.) in any body lumen. Any reference to a colonoscope should be understood to be applicable to endoscopes generally, and similarly, any reference to a colon should be understood to be applicable to any body lumen.

[0047] With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.

[0048] It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a

system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”

[0049] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0050] As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 articles refers to groups having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.

[0051] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

EXAMPLE EMBODIMENTS

1. A method for treating a diverticulum formed in a body lumen, the method comprising:

injecting a sterile fluid between a mucosal layer of the diverticulum and a serosal layer of the diverticulum to form an expanded cavity in the diverticulum comprising the sterile fluid;

injecting a filler material in the expanded cavity; and

removing at least a portion of the sterile fluid from the expanded cavity.

2. The method of Embodiment 1, wherein a volume of the expanded cavity is about the same as a volume of the diverticulum.

3. The method of any one of Embodiments 1-2, wherein injecting the sterile fluid between the mucosal layer of the diverticulum and the serosal layer of the diverticulum comprises moving the mucosal layer of the diverticulum toward an interior region of the body lumen.

4. The method of any one of Embodiments 1-3, wherein the sterile fluid is isotonic.

5. The method of any one of Embodiments 1-4, wherein the sterile fluid comprises saline.

6. The method of any one of Embodiments 1-5, wherein the sterile fluid is injected through a needle inserted through the mucosal layer.

7. The method of any one of Embodiments 1-6, further comprising maintaining a pressure in the expanded cavity below a pre-determined pressure.

8. The method of any one of Embodiments 1-7, wherein the filler material comprises at least one of a polymer, a polysaccharide, hydrophilic colloids, sclerosing agents, microspheres, or autologous cells.

9. The method of any one of Embodiments 1-8, wherein the filler material is injected into the expanded cavity at about the same time that the sterile fluid is removed from the expanded cavity.

10. The method of any one of Embodiments 1-9, wherein a volume of the filler material injected into the expanded cavity is about the same as a volume of the sterile fluid injected into the expanded cavity.

11. The method of any one of Embodiments 1-10, further comprising inserting a distal end of a flexible needle into a region of the diverticulum between the mucosal layer of the diverticulum and the serosal layer of the diverticulum,

wherein injecting the sterile fluid between the mucosal layer of the diverticulum and the serosal layer of the diverticulum comprises displacing the sterile fluid through the needle into the region of the diverticulum between the mucosal layer of the diverticulum and the serosal layer of the diverticulum.

12. The method of Embodiment 11, further comprising:

advancing a flexible tubular assembly through the body lumen to dispose a distal end of the tubular assembly near the diverticulum; and

disposing the flexible needle within a lumen of the tubular assembly, the flexible needle extending at least from a proximal end of the tubular assembly to a distal end of the tubular assembly.

13. The method of any one of Embodiments 11-12, wherein injecting a filler material in the expanded cavity comprises displacing the filler material through the flexible needle into the expanded cavity.

14. The method of any one of Embodiments 11-13, further comprising inserting an overtube into the expanded cavity, wherein the flexible needle is disposed within the overtube and adjustably extends from a distal end of the overtube, and

wherein removing at least a portion of the sterile fluid from the expanded cavity comprises displacing the sterile fluid through the overtube to a proximal end of the overtube.

15. The method of any one of Embodiments 11-14, further comprising moving a distal end of the flexible needle deeper into the expanded cavity towards the serosal layer.

16. The method of any one of Embodiments 11-15, wherein the body lumen comprises an intestine.

17. A needle for treating a diverticulum formed in a body lumen, the needle comprising:

a flexible overtube comprising a lumen;

a flexible shaft at least partially disposed within the lumen of the flexible overtube, the flexible shaft configured to adjustably extend from a distal end of the flexible overtube;

a cutting tip at a distal end of the flexible shaft, the cutting tip comprising an opening fluidly coupled to the lumen of the flexible shaft;

an input port fluidly coupled to the opening of the cutting tip; and

an output port fluidly coupled to a proximal end of the lumen of the overtube.

18. The needle of Embodiment 17, wherein the flexible overtube has a diameter of no more than about 3 mm.

19. The needle of any one of Embodiments 17-18, wherein the flexible shaft is configured to adjustably extend a distance of no more than about 2 cm from the distal end of the flexible overtube.

20. The needle of any one of Embodiments 17-19, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is from about 1 to about 3 mm.

21. The needle of any one of Embodiments 17-19, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is about the same as a depth of a region between a mucosal layer and a serosal layer of the diverticulum in the body lumen.

22. The needle of any one of Embodiments 17-20, wherein the input port comprises a fastener configured to fluidly couple with a fluid delivery device.

23. The needle of any one of Embodiments 17-22, wherein the input port comprises a fastener configured to fluidly couple with a pressure sensor.

24. The needle of any one of Embodiments 17-23, wherein the output port comprises a fastener configured to fluidly couple with a reservoir.

25. The needle of any one of Embodiments 17-24, wherein the distal end of the flexible overtube is configured to be inserted through a mucosal layer.

26. A system for treating a diverticulum formed in a body lumen, the system comprising:

a flexible tubular assembly comprising a plurality of lumens, the flexible tubular assembly configured to advance through the body lumen;

a light source at least partially disposed in a first lumen of the tubular assembly;

a viewing lens at least partially disposed in a second lumen of the tubular assembly; and

a needle at least partially disposed in a third lumen of the tubular assembly and configured to adjustably extend from a distal end of the tubular assembly, the needle comprising:

a flexible overtube comprising a lumen;

a flexible shaft at least partially disposed within the lumen of the flexible overtube, the flexible shaft configured to adjustably extend from a distal end of the flexible overtube;

a cutting tip at a distal end of the flexible shaft, the cutting tip comprising an opening fluidly coupled to the lumen of the flexible shaft;

an input port fluidly coupled to the opening of the cutting tip; and

an output port fluidly coupled to a distal end of the lumen of the overtube.

27. The system of Embodiment 26, further comprising a syringe fluidly coupled to the input port of the needle.

28. The system of Embodiment 27, wherein the syringe contains a sterile fluid.

29. The system of Embodiment 27, wherein the syringe contains a filler material.

30. The system of any one of Embodiments 26-29, further comprising a pressure sensor fluidly coupled to the input port.

31. The system of any one of Embodiments 26-30, further comprising a pump fluidly coupled to the input port and configured to displace a fluid through the needle.

32. The system of Embodiment 31, further comprising a processor in communication with the pressure sensor and the pump, the processor configured to reduce a flow rate of the pump if the pressure sensor measures a pressure above a pre-determined value.

33. The system of any one of Embodiments 26-32, a volumetric sensor fluidly coupled to the input port and configured to measure an amount of fluid injected through the needle.

34. The system of any one of Embodiments 26-33, a volumetric sensor fluidly coupled to the output port and configured to measure an amount fluid received through the overtube.

35. The system of any one of Embodiments 26-34, wherein the flexible shaft is configured to adjustably extend a distance of no more than about 2 cm from the distal end of the flexible overtube.

36. The system of any one of Embodiments 26-35, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is from about 1 mm to about 3 mm.

37. The system of any one of Embodiments 26-36, further comprising a reservoir fluidly coupled to the overtube.

38. A kit for treating a diverticulum formed in a body lumen, the kit comprising:
a flexible tubular assembly configured to be advanced in a body lumen;
a light source configured to be at least partially disposed within a first lumen of the flexible tubular assembly;

a lens configured to be at least partially disposed within a second lumen of the flexible tubular assembly; and

a needle configured to be at least partially disposed within a third lumen of the flexible tubular assembly, the needle comprising:

a flexible overtube comprising a lumen;

a flexible shaft at least partially disposed within the lumen of the flexible overtube, the flexible shaft configured to adjustably extend from a distal end of the flexible overtube;

a cutting tip at a distal end of the flexible shaft, the cutting tip comprising an opening fluidly coupled to the lumen of the flexible shaft;

an input port fluidly coupled to the opening of the cutting tip; and

an output port fluidly coupled to a distal end of the lumen of the overtube.

39. The kit of Embodiment 38, further comprising a pressure sensor configured to be coupled with the input port of the needle.

40. The kit of any one of Embodiments 38-39, further comprising a first volumetric sensor configured to be coupled with the input port of the needle.

41. The kit of any one of Embodiments 38-40, further comprising a second volumetric sensor configured to be coupled with the output port of the needle.

42. The kit of any one of Embodiments 38-41, further comprising a syringe configured to be fluidly coupled to the input port.

43. The kit of any one of Embodiments 38-42, further comprising a sterile fluid configured to be injected between a mucosal layer of the diverticulum and a serosal layer of the diverticulum.

44. The kit of any one of Embodiments 38-43, further comprising a filler material configured to be injected between a mucosal layer of the diverticulum and a serosal layer of the diverticulum.

45. The kit of any one of Embodiments 38-44, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is from about 1 to about 3 mm.

WHAT IS CLAIMED IS:

1. A method for treating a diverticulum formed in a body lumen, the method comprising:

injecting a sterile fluid between a mucosal layer of the diverticulum and a serosal layer of the diverticulum to form an expanded cavity in the diverticulum comprising the sterile fluid;

injecting a filler material in the expanded cavity; and

removing at least a portion of the sterile fluid from the expanded cavity.

2. The method of Claim 1, wherein a volume of the expanded cavity is about the same as a volume of the diverticulum.

3. The method of Claim 1, wherein injecting the sterile fluid between the mucosal layer of the diverticulum and the serosal layer of the diverticulum comprises moving the mucosal layer of the diverticulum toward an interior region of the body lumen.

4. The method of Claim 1, wherein the sterile fluid is isotonic.

5. The method of Claim 1, wherein the sterile fluid comprises saline.

6. The method of Claim 1, wherein the sterile fluid is injected through a needle inserted through the mucosal layer.

7. The method of Claim 1, further comprising maintaining a pressure in the expanded cavity below a pre-determined pressure.

8. The method of Claim 1, wherein the filler material comprises at least one of a polymer, a polysaccharide, hydrophilic colloids, sclerosing agents, microspheres, or autologous cells.

9. The method of Claim 1, wherein the filler material is injected into the expanded cavity at about the same time that the sterile fluid is removed from the expanded cavity.

10. The method of Claim 1, wherein a volume of the filler material injected into the expanded cavity is about the same as a volume of the sterile fluid injected into the expanded cavity.

11. The method of Claim 1, further comprising inserting a distal end of a flexible needle into a region of the diverticulum between the mucosal layer of the diverticulum and the serosal layer of the diverticulum,

wherein injecting the sterile fluid between the mucosal layer of the diverticulum and the serosal layer of the diverticulum comprises displacing the sterile fluid through

the needle into the region of the diverticulum between the mucosal layer of the diverticulum and the serosal layer of the diverticulum.

12. The method of Claim 11, further comprising:

advancing a flexible tubular assembly through the body lumen to dispose a distal end of the tubular assembly near the diverticulum; and

disposing the flexible needle within a lumen of the tubular assembly, the flexible needle extending at least from a proximal end of the tubular assembly to a distal end of the tubular assembly.

13. The method of Claim 11, wherein injecting a filler material in the expanded cavity comprises displacing the filler material through the flexible needle into the expanded cavity.

14. The method of Claim 11, further comprising inserting an overtube into the expanded cavity, wherein the flexible needle is disposed within the overtube and adjustably extends from a distal end of the overtube, and

wherein removing at least a portion of the sterile fluid from the expanded cavity comprises displacing the sterile fluid through the overtube to a proximal end of the overtube.

15. The method of Claim 11, further comprising moving a distal end of the flexible needle deeper into the expanded cavity towards the serosal layer.

16. The method of Claim 11, wherein the body lumen comprises an intestine.

17. A needle for treating a diverticulum formed in a body lumen, the needle comprising:

a flexible overtube comprising a lumen;

a flexible shaft at least partially disposed within the lumen of the flexible overtube, the flexible shaft configured to adjustably extend from a distal end of the flexible overtube;

a cutting tip at a distal end of the flexible shaft, the cutting tip comprising an opening fluidly coupled to the lumen of the flexible shaft;

an input port fluidly coupled to the opening of the cutting tip; and

an output port fluidly coupled to a proximal end of the lumen of the overtube.

18. The needle of Claim 17, wherein the flexible overtube has a diameter of no more than about 3 mm.

19. The needle of Claim 17, wherein the flexible shaft is configured to adjustably extend a distance of no more than about 2 cm from the distal end of the flexible overtube.

20. The needle of Claim 17, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is from about 1 to about 3 mm.

21. The needle of Claim 17, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is about the same as a depth of a region between a mucosal layer and a serosal layer of the diverticulum in the body lumen.

22. The needle of Claim 17, wherein the input port comprises a fastener configured to fluidly couple with a fluid delivery device.

23. The needle of Claim 17, wherein the input port comprises a fastener configured to fluidly couple with a pressure sensor.

24. The needle of Claim 17, wherein the output port comprises a fastener configured to fluidly couple with a reservoir.

25. The needle of Claim 17, wherein the distal end of the flexible overtube is configured to be inserted through a mucosal layer.

26. A system for treating a diverticulum formed in a body lumen, the system comprising:

a flexible tubular assembly comprising a plurality of lumens, the flexible tubular assembly configured to advance through the body lumen;

a light source at least partially disposed in a first lumen of the tubular assembly;

a viewing lens at least partially disposed in a second lumen of the tubular assembly; and

a needle at least partially disposed in a third lumen of the tubular assembly and configured to adjustably extend from a distal end of the tubular assembly, the needle comprising:

a flexible overtube comprising a lumen;

a flexible shaft at least partially disposed within the lumen of the flexible overtube, the flexible shaft configured to adjustably extend from a distal end of the flexible overtube;

a cutting tip at a distal end of the flexible shaft, the cutting tip comprising an opening fluidly coupled to the lumen of the flexible shaft;

an input port fluidly coupled to the opening of the cutting tip; and
an output port fluidly coupled to a distal end of the lumen of the
overtube.

27. The system of Claim 26, further comprising a syringe fluidly coupled to the input port of the needle.

28. The system of Claim 27, wherein the syringe contains a sterile fluid.

29. The system of Claim 27, wherein the syringe contains a filler material.

30. The system of Claim 26, further comprising a pressure sensor fluidly coupled to the input port.

31. The system of Claim 26, further comprising a pump fluidly coupled to the input port and configured to displace a fluid through the needle.

32. The system of Claim 31, further comprising a processor in communication with the pressure sensor and the pump, the processor configured to reduce a flow rate of the pump if the pressure sensor measures a pressure above a pre-determined value.

33. The system of Claim 26, a volumetric sensor fluidly coupled to the input port and configured to measure an amount of fluid injected through the needle.

34. The system of Claim 26, a volumetric sensor fluidly coupled to the output port and configured to measure an amount fluid received through the overtube.

35. The system of Claim 26, wherein the flexible shaft is configured to adjustably extend a distance of no more than about 2 cm from the distal end of the flexible overtube.

36. The system of Claim 26, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is from about 1 mm to about 3 mm.

37. The system of Claim 26, further comprising a reservoir fluidly coupled to the overtube.

38. A kit for treating a diverticulum formed in a body lumen, the kit comprising:
a flexible tubular assembly configured to be advanced in a body lumen;
a light source configured to be at least partially disposed within a first lumen of the flexible tubular assembly;

a lens configured to be at least partially disposed within a second lumen of the flexible tubular assembly; and

a needle configured to be at least partially disposed within a third lumen of the flexible tubular assembly, the needle comprising:

a flexible overtube comprising a lumen;

a flexible shaft at least partially disposed within the lumen of the flexible overtube, the flexible shaft configured to adjustably extend from a distal end of the flexible overtube;

a cutting tip at a distal end of the flexible shaft, the cutting tip comprising an opening fluidly coupled to the lumen of the flexible shaft;

an input port fluidly coupled to the opening of the cutting tip; and

an output port fluidly coupled to a distal end of the lumen of the overtube.

39. The kit of Claim 38, further comprising a pressure sensor configured to be coupled with the input port of the needle.

40. The kit of Claim 38, further comprising a first volumetric sensor configured to be coupled with the input port of the needle.

41. The kit of Claim 38, further comprising a second volumetric sensor configured to be coupled with the output port of the needle.

42. The kit of Claim 38, further comprising a syringe configured to be fluidly coupled to the input port.

43. The kit of Claim 38, further comprising a sterile fluid configured to be injected between a mucosal layer of the diverticulum and a serosal layer of the diverticulum.

44. The kit of Claim 38, further comprising a filler material configured to be injected between a mucosal layer of the diverticulum and a serosal layer of the diverticulum.

45. The kit of Claim 38, wherein the flexible shaft further comprises a marking at a fixed distance from the opening of the cutting tip, wherein the fixed distance is from about 1 to about 3 mm.




FIG. 1

2 / 13




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2013/040069

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61B 17/00 (2013.01)

USPC - 604/514

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61B 17/00, 17/12, 17/34, 17/94; A61M 29/00, 29/02 (2013.01)

USPC - 128/898; 604/514, 540; 606/185, 190, 192

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

CPC - A61B 17/00, 17/00491, 17/0057, 17/12181, 17/121816, 17/3478, 2017/00269 (2013.01)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Patbase, Google Patents

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/0174306 A1 (MITELBERG et al) 08 July 2010 (08.07.2010) entire document	17-21
---		-----
Y		22-45
Y	US 5,536,242 A (WILLARD et al) 16 July 1996 (16.07.1996) entire document	22-24, 39-41
Y	US 2005/0149099 A1 (YAMANO et al) 07 July 2005 (07.07.2005) entire document	25, 27-29, 42
Y	WO 02/089655 A2 (IMRAN et al) 14 November 2002 (14.11.2002) entire document	26-45
Y	US 2011/0313343 A1 (MILUTINOVIC et al) 22 December 2011 (22.12.2011) entire document	30-34
A	US 2011/0277778 A1 (ALEXANDER et al) 17 November 2011 (17.11.2011) entire document	1-45
A	US 2011/0060358 A1 (STOKES et al) 10 March 2011 (10.03.2011) entire document	1-45

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 July 2013

Date of mailing of the international search report

24 JUL 2013

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774